Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: A model-based analysis

AIDS

Volumn 26, Issue 13, 2012, Pages 1663-1672

  Hamers, Raph L ^a   Sawyer, A W ^b   Tuohy, Martin ^c   Stevens, Wendy S ^d   De Wit, Tobias F Rinke ^a   Hill, Andrew M ^e  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MetaVirology Ltd   (United Kingdom)

^c Therapy Management International   (France)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

antiretroviral therapy; cost effectiveness; diagnostic strategy; HIV 1; sub Saharan Africa; viral load

Indexed keywords

ANTIRETROVIRUS AGENT;

AFRICA SOUTH OF THE SAHARA; ARTICLE; CD4 LYMPHOCYTE COUNT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; LABORATORY TEST; LIFE EXPECTANCY; MARKOV MODEL; MATHEMATICAL MODEL; MONEY; MONITORING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SYMPTOM; TREATMENT OUTCOME; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CLINICAL LABORATORY TECHNIQUES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; LIFE EXPECTANCY; MALE; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; SENTINEL SURVEILLANCE; TREATMENT FAILURE; VIRAL LOAD;

EID: 84865460130     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283560678     Document Type: Article

References (40)

1. Jahn A, Floyd S, Crampin AC, Mwaungulu F, Mvula H, Munthali F, et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 2008; 371:1603-1611. (Pubitemid 351626844)
2. Joint United Nations Programme on HIV/AIDS. Global report: UNAIDS report on the global HIV epidemic 2010. 2010. http://www.unaids.org/documents/20101123- GlobalReport-em.pdf. [Accessed 1 September 2011].
3. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010. 2010. http://www.who.int/hiv/pub/2010progress report/report/en/index.html. [Accessed 1 September 2011].
4. DHHS. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo. nih. gov/content files/lvguidelines/AdultandAdolescentGL.pdf. [Accessed 14 October 2011].
5. European AIDS Clinical Society. Guidelines clinical management and treatment of HIV infected adults in Europe. Available at: http://www. europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EACSGuidelines-v6. 0-English.pdf. Version6, October 2011.
6. Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, Kityo C, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised noninferiority trial. Lancet 2010; 375:123-131.
7. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22:1971-1977.
8. Reynolds SJ, Nakigozi G, Newell K, Ndyanabo A, Galiwongo R, Boaz I, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009; 23:697-700.
9. Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58:23-32.
10. van Oosterhout JJ, Bodasing N, Kumwenda JJ, Nyirenda C, Mallewa J, Cleary PR, et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health 2005; 10:464-470. (Pubitemid 40712431)
11. Davies MA, Boulle A, Eley B, Moultrie H, Technau K, Rabie H, et al. Accuracy of immunological criteria for identifying virological failure in children on antiretroviral therapy: the IeDEA Southern Africa Collaboration. Trop Med Int Health 2011 Aug doi: 10. 1111/j. 1365-3156. 2011. 02854. x. [Epub ahead of print]
12. Sigaloff K, Hamers R, Wallis C, Kityo C, Siwale M, Conradie F, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations: two arguments for viral load monitoring in Africa. In: Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections; February 2011; Boston, USA; abstract #679.
13. Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9:409-417.
14. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-1134.
15. Phillips AN, Pillay D, Garnett G, Bennett D, Vitoria M, Cambiano V, Lundgren J. Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings. AIDS 2011; 25:843-850.
16. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
17. Bendavid E, Young SD, Katzenstein DA, Bayoumi AM, Sanders GD, Owens DK. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med 2008; 168:1910-1918.
18. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008; 371:1443-1451. (Pubitemid 351635534)
19. Vijayaraghavan A, Efrusy MB, Mazonson PD, Ebrahim O, Sanne IM, Santas CC. Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developingworld. J AcquirImmuneDefic Syndr 2007; 46:91-100. (Pubitemid 47507438)
20. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2010 revision. 2010. http://whqlibdoc.who.int/publications/2010/9789241599764-eng. pdf. [Accessed 1 September 2011].
21. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010; 10:155-166.
22. Benzie AA, Bansi LK, Sabin CA, Portsmouth S, Hill T, Johnson M, et al. Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. AIDS 2007; 21:1423-1430. (Pubitemid 46988002)
23. Keiser O, Tweya H, Braitstein P, Dabis F, MacPhail P, Boulle A, et al. Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health 2010; 15:251-258.
24. Pujades-Rodriguez M, Balkan S, Arnould L, Brinkhof MA, Calmy A. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA 2010; 304:303-312.
25. Long L, Fox M, Sanne I, Rosen S. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS 2010; 24:915-919.
26. Clinton HIV AIDS Initiative. ARV Pricelist 2011. 2011. http://www.clintonfoundation.org/what-we-do/clinton-hiv-aids-initia tive/information-center-resources. [Accessed 1 October 2011]
27. Clinton HIV AIDS Initiative. HIV/AIDS Diagnostic Pricing Outlook 2009. 2009. http://www.who.int/hiv/topics/treatment/costing-clinton-diagnostic.pdf. [Accessed 1 October 2011]
28. Wilson D, Keiluhu AK, Kogrum S, Reid T, Seriratana N, Ford N, et al. HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. Trans R Soc Trop Med Hyg 2009; 103:601-606.
29. Keiser O, Chi BH, Gsponer T, Boulle A, Orrell C, Phiri S, et al. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa. AIDS 2011; 25:1761-1769.
30. World Health Organization. UNITAID HIV/AIDS Diagnostic Technology Landscape. October 2011. http://www.unitaid.eu/about/MarketApproaches/ Publications/2011-Update-HIV-Diag nostic-Technology-Landscape.pdf. [Accessed 1 December 2011].
31. Phillips AN, Youle M, Lampe F, Sabin CA, Hill A, Ransom D, et al. CD4 cell count changes in individuals with counts above 500 cells/mm and viral loads below 50 copies/ml on antiretroviral therapy. AIDS 2002; 16:1073-1075. (Pubitemid 34499433)
32. Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364:51-62.
33. Ministry of Health. Clinical Management of HIV in Children and Adults. Malawi Integrated Guidelines for Providing HIV Services. Malawi, 2011. http://www.medcol.mw/paediatrics/uploads/MalawiHIVguidelines2011.pdf. [Accessed 1 May 2011].
34. Bagchi S, Kempf MC, Westfall AO, Maherya A, Willig J, Saag MS.Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? Clin Infect Dis 2007; 44:135-138. (Pubitemid 44968998)
35. Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, Goemaere E, et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 2007; 44: 128-134. (Pubitemid 44968997)
36. Walensky RP, Freedberg KA, Weinstein MC. Monitoring of antiretroviral therapy in low-resource settings. Lancet 2008; 372:288; author reply 289. (Pubitemid 352020428)
37. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between lowincome and high-income countries. Lancet 2006; 367:817-824.
38. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Traisaithit P, Barbier S, Techapornroong M, et al.PHPT-3: a randomized clinical trial comparing CD4 vs viral load ART monitoring/switching strategies in Thailand. In: Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections; February 2011; Boston, MA; abstract 44.
39. Saag M, Westfall A, Luhanga D, Mulenga P, Chi B, Mulenga L, et al. A cluster randomized trial of routine vs discretionary viral load monitoring among adults starting ART: Zambia. In: Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections; February 2011; Seattle, WA; abstract 87.
40. Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and metaanalysis. AIDS 2012; 26:929-938.